Castle Biosciences reveals melanoma test study findings at SSO 2024

US-based molecular diagnostics company Castle Biosciences has reported positive study data of its gene expression profile (GEP) test, DecisionDx-UM, to predict the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM).